Employees: 58
Size Daiken Biomedical (7780.TW) is a Taiwan Health Care company (Pharmaceuticals: Other) with a market value of $342M, the 577th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$14.50 on 18 Nov 2026.
Performance Over six months the shares fell 19.0%, against -22.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth The operating margin is 17.8% (peer median 8.5%).
Valuation It trades at 3.0× enterprise value to sales against a peer median of 2.2× (9th most expensive of 20).
Capital Return on invested capital runs 46.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | |
|---|---|---|
| Revenue | NT$2.34B | NT$1.90B |
| Revenue growth | — | — |
| Gross profit | NT$1.43B | NT$1.21B |
| EBITDA | NT$425M | NT$295M |
| Net income | NT$468M | NT$338M |
| Free cash flow | NT$207M | NT$270M |
| Capital expenditure | NT$322M | NT$5.16M |
| Total debt | NT$17.0M | NT$123M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7780.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.7% | -11.4% | 8th highest of 21 |
| 6-month return | -19.0% | -22.3% | 7th highest of 21 |
| Distance from 52-week high | -50.7% | -41.8% | 3rd lowest of 21 |
| Operating margin | 17.8% | 8.5% | 8th highest of 21 |
| EV / Sales | 3.0× | 2.2× | 9th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | -1.6% | 1.4% | 4th least demanding of 14 |
| ROIC minus cost of capital | +46.7 pp | -0.1 pp | 2nd highest of 20 |
| EV / EBITDA | 16.5× | 4.6× | most expensive of 5 |
| Net debt / EBITDA | -10.1× | -1.3× | least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Daiken Biomedical 7780.TW | Taiwan | $342M | -19% | n/a | 18% | 3.0× | -1.6% | n/a |
| Grape King Bio 1707.TW | Taiwan | $342M | -27% | -5% | 19% | 1.0× | -17.2% | +2.3% |
| Boiron BOI.PA | France | $367M | -31% | -2% | 5% | 0.6× | -0.8% | -0.5% |
| Zhejiang Xinguang Pharmaceutical 300519.SZ | China | $319M | -15% | +5% | 27% | 5.1× | 3.1% | -1.3% |
| TCI 8436.TWO | Taiwan | $312M | -24% | -4% | 18% | 1.3× | -12.1% | -3.2% |
| Weihai Baihe Biology Technological 603102.SS | China | $296M | -22% | +18% | 14% | 0.9× | -11.8% | +9.6% |
| Tibet Aim Pharm 002826.SZ | China | $407M | -22% | +13% | 14% | 2.9× | 0.4% | +1.0% |
| Myung in Pharm 317450.KS | South Korea | $466M | -20% | +7% | 35% | 0.7× | n/a | n/a |
| Lionco Pharmaceutical 603669.SS | China | $474M | +4% | -6% | -17% | 8.4× | n/a | n/a |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $532M | -2% | -4% | 21% | 3.0× | 1.4% | +7.0% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $548M | -9% | +6% | 6% | 3.3× | 15.4% | +6.5% |
| ArriVent BioPharma AVBP | United States | $564M | -60% | n/a | -3,620% | 34.2× | n/a | n/a |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $583M | -23% | +21% | 11% | 3.8× | 19.1% | +12.1% |
| ABA Chemicals 300261.SZ | China | $592M | -26% | -16% | -23% | 4.9× | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $613M | -30% | 0% | 0% | 2.0× | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $641M | -22% | -28% | -25% | 1.8× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $668M | -33% | +8% | 4% | 1.5× | 4.0% | +13.5% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | 3.4× | 0.4% | +4.8% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | 2.2× | 2.1% | -1.3% |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 1.5× | 14.1% | +15.6% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | n/a | n/a | n/a |